Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
Phase 3
Completed
NCT04662710
| Condition | Advanced/Metastatic Gastroesophageal Adenocarcinoma |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Merck Sharp & Dohme LLC |
|---|
| Status | Completed |
|---|
| Enrollment | 895 participants |
|---|
| Interventions | Pembrolizumab, Lenvatinib, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin) |
|---|
| Start date | Dec 30, 2020 |
|---|
| Completion date | Oct 29, 2024 |
|---|
| Results posted | Nov 28, 2025 |
|---|
Summary
The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Up to ~21 days · Participants
| Part 1 : Lenvatinib + Pembrolizumab + Chemotherapy | 2 Participants |
|---|
Part 1: Number of Participants With Adverse Events (AEs)
Up to ~44 months · Participants
| Safety Run-In: Lenvatinib + Pembrolizumab + Chemotherapy | 15 Participants |
|---|
Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE
Up to ~29 months · Participants
| Safety Run-In: Lenvatinib + Pembrolizumab + Chemotherapy | 5 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.